New arthritis drug put to the sun safety test

NCT ID NCT05844735

Completed Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether the experimental drug SAR441566, being developed for rheumatoid arthritis, makes skin more sensitive to ultraviolet (UV) light. Sixty healthy adults aged 18 to 55 received either the drug, a placebo, or ciprofloxacin (a known sun-sensitizer). Researchers measured skin redness after UV exposure to see if the drug increases sunburn risk. The results will help determine if the drug is safe to use without extra sun precautions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR441566
What this could lead to: If successful, this study could show that SAR441566 is safe to use without extra sun sensitivity, supporting its further development for rheumatoid arthritis.
What could go wrong: This is an early Phase 1 study in only 60 healthy people, not patients. It only tests sun sensitivity, not whether the drug works for arthritis. The drug may still fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

TKL Research, Inc. Site Number : 8400001

Fair Lawn, New Jersey, 07410, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.